Thursday, 27 May 2010
AMRI cuts back in US
AMRI is closing its Rensselaer, NY, facility, with the loss of 50 jobs. A further 30 jobs will be lost at its other US facilities while the company plans to add 180 jobs in Asia as it invests $30m in its international facilities.
Albany Business Journal
Tuesday, 25 May 2010
Pfizer cuts eight manufacturing sites; cuts back at others
Pfizer plans to cease operations at eight plants in Ireland, Puerto Rico and the United States by late 2015 and reduce activities at six factories in those countries, plus Germany and Britain. The cuts will result in 6000 job losses.
Reuters
Consortium passes passes flu vax manufacturing test
A consortium led by Xcellerex has successfully demonstrated the production of purified swine flu H1 hemagglutinin (California strain) in 42 days starting from the amino acid sequence of the protein. The test results exceeded the goal for rate of production by at least 10 fold and exceeded all product quality specifications. The team, guided by BioPharm Services, combined Pfenex’s Pseudomonas fluorescens-based rapid strain engineering platform with Xcellerex’s microbial high speed process development and single-use manufacturing technologies and deltaDOT’s label free CE-based analytical technology.
In-Pharma Technologist
Thursday, 13 May 2010
Wednesday, 5 May 2010
American Peptide expands peptide production capacity
American Peptide has expanded its Vista, California cGMP peptide production facility. The large-scale facility expansion includes four new peptide purification suites. The company will also add two new synthesis suites and multi-kg lyophilisation capacity.
In-Pharma Technologist
BioUetikon adds capacity
BioUetikon has installed a single use bioreactor train with 50L, 250L and 1000L capacity tanks. The train also includes complimentary scale GMP buffer and media preparation.
BioUetikon
Cambrex Q1 sales decline
Cambrex's first quarter 2010 sales declined 6.4%, compared to 2009, to $56.2m. Cambrex said the decrease is primarily due to the timing of orders for two APIs manufactured under long-term supply agreements, a customer supply chain disruption for an API manufactured under a long-term supply agreement, and a feed additive for which a contract expired. Additionally, Cambrex said lower pricing of certain generic APIs and a product utilising its drug delivery technology also contributed to the decrease.
Cambrex
Tuesday, 4 May 2010
DSM to build Australian biopharma plant
The Queensland and Australian governments will fund Australia's first biopharmaceutical contract manufacturing facility in Brisbane. The 7000m3 facility to be built and operated by DSM will provide mammalian process development and cGMP clinical and commercial manufacturing services. The new facility is anticipated to be commissioned and operational in 2013.
In-Pharma Technologist
BPTF introduces API quality agreement
Socma's Bulk Pharmaceuticals Task Force (BPTF) has developed a template to help manufacturers and customers standardise API quality agreements and comply with US regulatory requirements.
Socma
